These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3802708)

  • 21. Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis.
    Debruyne D; Gram LF; Grollier G; Camsonne R; Agron L; Dao MT; Lacotte J; Bigot MC; Moulin M
    Int J Clin Pharmacol Res; 1989; 9(5):319-25. PubMed ID: 2625371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The comparative effects of verapamil and a new dihydropyridine calcium channel blocker on digoxin pharmacokinetics.
    Johnson BF; Wilson J; Marwaha R; Hoch K; Johnson J
    Clin Pharmacol Ther; 1987 Jul; 42(1):66-71. PubMed ID: 2954736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of oral verapamil therapy on antipyrine clearance.
    Rumiantsev DO; Piotrovskii VK; Riabokon OS; Slastnikova ID; Kokurina EV; Metelitsa VI
    Br J Clin Pharmacol; 1986 Nov; 22(5):606-9. PubMed ID: 3790408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of verapamil on the pharmacokinetics of adriamycin.
    Kerr DJ; Graham J; Cummings J; Morrison JG; Thompson GG; Brodie MJ; Kaye SB
    Cancer Chemother Pharmacol; 1986; 18(3):239-42. PubMed ID: 3026675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative evaluation of the effects of labetalol, verapamil and diltiazem on antipyrine and indocyanine green clearances.
    Rocci ML; Vlasses PH; Lener ME; Fruncillo RA; Sirgo MA
    J Clin Pharmacol; 1989 Oct; 29(10):891-5. PubMed ID: 2592580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered?
    Rameis H
    Int J Clin Pharmacol Ther Toxicol; 1985 Mar; 23(3):145-53. PubMed ID: 3997300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of quinidine with anticonvulsant drugs.
    Data JL; Wilkinson GR; Nies AS
    N Engl J Med; 1976 Mar; 294(13):699-702. PubMed ID: 1250281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol.
    Kessler KM; Humphries WC; Black M; Spann JF
    Am Heart J; 1978 Nov; 96(5):627-35. PubMed ID: 263396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations.
    Bauer LA; Horn JR; Pettit H
    Ther Drug Monit; 1996 Feb; 18(1):46-52. PubMed ID: 8848820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased quinidine plasma concentrations during administration of verapamil: a new quinidine-verapamil interaction.
    Trohman RG; Estes DM; Castellanos A; Palomo AR; Myerburg RJ; Kessler KM
    Am J Cardiol; 1986 Mar; 57(8):706-7. PubMed ID: 3953464
    [No Abstract]   [Full Text] [Related]  

  • 31. Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans.
    Abernethy DR; Egan JM; Dickinson TH; Carrum G
    J Pharmacol Exp Ther; 1988 Mar; 244(3):994-9. PubMed ID: 3252045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Interactions between quinidine and verapamil].
    Mazurek W; Halawa B
    Pol Tyg Lek; 1989 Feb; 44(6):156-7. PubMed ID: 2813172
    [No Abstract]   [Full Text] [Related]  

  • 33. Accumulation of 3-hydroxyquinidine following chronic quinidine therapy.
    Ackerman BH; Olsen KM; Pappas AA
    DICP; 1991; 25(7-8):867-9. PubMed ID: 1949948
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine.
    Laganière S; Davies RF; Carignan G; Foris K; Goernert L; Carrier K; Pereira C; McGilveray I
    Clin Pharmacol Ther; 1996 Sep; 60(3):255-64. PubMed ID: 8841148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of quinidine and three of its metabolites in man.
    Rakhit A; Holford NH; Guentert TW; Maloney K; Riegelman S
    J Pharmacokinet Biopharm; 1984 Feb; 12(1):1-21. PubMed ID: 6747817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reverse-phase liquid chromatography and pharmacokinetic study of two hydroxylated analogues of quinidine in dogs.
    Leroyer R; Jarreau C; Pays M; Varoquaux O; Advenier C
    J Pharm Sci; 1984 Jun; 73(6):844-6. PubMed ID: 6547483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of quinidine gluconate for nonlinear kinetics following chronic dosing.
    Russo J; Russo ME; Smith RA; Pershing LK
    J Clin Pharmacol; 1982; 22(5-6):264-70. PubMed ID: 7107973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs.
    Rakhit A; Guentert TW; Holford NH; Verhoeven J; Riegelman S
    Eur J Drug Metab Pharmacokinet; 1984; 9(4):315-24. PubMed ID: 6532805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concentration-time effects of quinidine disposition kinetics in rhesus monkeys.
    Ueda CT; Ballard B; Rowland M
    J Pharmacol Exp Ther; 1977 Mar; 200(3):459-68. PubMed ID: 403278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of cimetidine on quinidine clearance.
    Kolb KW; Garnett WR; Small RE; Vetrovec GW; Kline BJ; Fox T
    Ther Drug Monit; 1984; 6(3):306-12. PubMed ID: 6506138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.